Terms: = Kidney tumors AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Prognosis
161 results:
1. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased EGFR expression by activating AhR and akt.
Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
[TBL] [Abstract] [Full Text] [Related]
2. Designing a predictive Framework: Immune-Related Gene-Based nomogram and prognostic model for kidney renal papillary cell carcinoma.
Lim A; Edderkaoui M; Zhang Y; Wang Q; Wang R; Pandol SJ; Ou Y
Int Immunopharmacol; 2024 Apr; 131():111878. PubMed ID: 38493693
[TBL] [Abstract] [Full Text] [Related]
3. EMX2 inhibits clear cell renal cell carcinoma progress via modulating akt/FOXO3a pathway.
Zhou X; Dong S; Zhou Y; He Z; Zhang Z; Liao L; Zou B; Zheng X; Peng K; Duan X
Mol Carcinog; 2024 May; 63(5):951-961. PubMed ID: 38362840
[TBL] [Abstract] [Full Text] [Related]
4. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit akt dephosphorylation and activate the akt-mTOR signaling pathway.
Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
[TBL] [Abstract] [Full Text] [Related]
5. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
6. SLFN11 promotes clear cell renal cell carcinoma progression via the PI3K/akt signaling pathway.
Wang HX; Zhao ZP; Du XY; Peng SL; Xu HY; Tang W; Yang L
Med Oncol; 2024 Jan; 41(2):54. PubMed ID: 38206539
[TBL] [Abstract] [Full Text] [Related]
7. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/akt/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma.
Wang X; Yao L; Li Z; Zhang J; Ruan M; Mulati Y; Gan Y; Zhang Q
Int J Biol Sci; 2024; 20(2):643-663. PubMed ID: 38169650
[No Abstract] [Full Text] [Related]
8. Doxycycline hydrochloride inhibits the progress of malignant rhabdoid tumor of kidney by targeting MMP17 and MMP1 through PI3K-akt signaling pathway.
Mi T; Zhang Z; Zhanghuang C; Jin L; Tan X; Liu J; Wu X; Li M; Wang J; Wang Z; Guo P; He D
Eur J Pharmacol; 2024 Feb; 964():176291. PubMed ID: 38158115
[TBL] [Abstract] [Full Text] [Related]
9. Molecular Expression and Prognostic Implications of Krüppel-Like Factor 3 (KLF3) in Clear Cell Renal Cell Carcinoma.
Wan B; Zhang W; Deng X; Lu Y; Zhang Z; Yang Y
Crit Rev Eukaryot Gene Expr; 2024; 34(2):45-59. PubMed ID: 38073441
[TBL] [Abstract] [Full Text] [Related]
10. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent akt pathway activation.
Liu T; Xiang W; Chen Z; Wang G; Cao R; Zhou F; Meng Z; Luo Y; Chen L
Cell Death Dis; 2023 Nov; 14(11):774. PubMed ID: 38008826
[TBL] [Abstract] [Full Text] [Related]
11. High PAQR4 mRNA Expression May Play a Key Role in prognosis of kidney Renal Papillary Cell Carcinoma.
Liu C; Cai W; Tang P; Li C
Ann Clin Lab Sci; 2023 Sep; 53(5):701-711. PubMed ID: 37945022
[TBL] [Abstract] [Full Text] [Related]
12. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors.
Kim B; Lee S; Moon KC
Hum Pathol; 2023 Dec; 142():1-6. PubMed ID: 37797754
[TBL] [Abstract] [Full Text] [Related]
13. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
[TBL] [Abstract] [Full Text] [Related]
14. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.
Lv Z; Wang M; Hou H; Tang G; Xu H; Wang X; Li Y; Wang J; Liu M
Int J Biol Sci; 2023; 19(11):3293-3306. PubMed ID: 37496990
[No Abstract] [Full Text] [Related]
15. PI3K/akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
16. BKM120 inhibits malignant rhabdoid tumor of the kidney through induction of apoptosis and G0/G1 phase arrest.
Liu J; Mi T; Zhang Z; Jin L; Li M; Zhanghuang C; Li M; Wang J; Wu X; Wang Z; Tan X; Wang Z; He D
Eur J Pharmacol; 2023 Jul; 951():175747. PubMed ID: 37142086
[TBL] [Abstract] [Full Text] [Related]
17. ADAM metallopeptidase with thrombospondin type 1 motif 16 is a potential marker for prognosis in clear cell renal cell carcinoma.
Bai C; Chen DG
Pathol Int; 2023 Jul; 73(7):297-305. PubMed ID: 37132990
[TBL] [Abstract] [Full Text] [Related]
18. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
[TBL] [Abstract] [Full Text] [Related]
19.
Qiao L; Zhang L; Wang H
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107702
[TBL] [Abstract] [Full Text] [Related]
20. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
Song C; Shang F; Tu W; Liu X
BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
[TBL] [Abstract] [Full Text] [Related]
[Next]
